Albert Barberà, new CEO of Biocat

The Biocat Board of Trustees, presided over by Catalan Minister of Health Boi Ruiz, has appointed Dr. Albert Barberà the new CEO of the organization. Barberà, who until now has served as director of the Girona Biomedical Research Institute (IDIBGi), will take over in January for Dra. Montserrat Vendrell, who was CEO of Biocat from 2007 through September of this year when she took the reigns of the Barcelona Institute of Science and Technology (BIST).

Albert Barberà (Barcelona, 1969) has a degree in Chemistry and Pharmacy and a PhD in Biochemistry and Molecular Biology from the University of Barcelona (UB). In addition to this scientific training, he also did a postgraduate degree in Financial Management and a Master of Scientific Leadership and Management. Over his career, he has obtained professional experience in both research and management of knowledge and innovation in the biomedical research environment and in health.

After a postdoctoral fellowship at the Mount Sinai School of Medicine and Rockefeller University in New York, Barberà joined the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), first as a researcher and later managing national and international projects. Since 2008, he has held several positions in science management, first as the manager of the Institute of Health Carlos III Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), later as scientific coordinator at IDIBAPS and, finally, as director of the IDIBGi, his current position.

“For me it is a privilege and a great professional challenge to take over as CEO of Biocat, leading projects that help strengthen the whole health ecosystem in the BioRegion of Catalonia,” highlights Albert Barberà, new CEO of Biocat.